中华血液学杂志
中華血液學雜誌
중화혈액학잡지
Chinese Journal of Hematology
2012年
1期
1-5
,共5页
李林萌%陈子兴%岑建农%沈宏杰%姚利%王元元%祁小飞
李林萌%陳子興%岑建農%瀋宏傑%姚利%王元元%祁小飛
리림맹%진자흥%잠건농%침굉걸%요리%왕원원%기소비
融合蛋白质类,AMLl -ETO%易位,遗传%白血病,非淋巴细胞,急性%复发
融閤蛋白質類,AMLl -ETO%易位,遺傳%白血病,非淋巴細胞,急性%複髮
융합단백질류,AMLl -ETO%역위,유전%백혈병,비림파세포,급성%복발
Fusion proteins,AML1-ETO%Translocation,genetic%Leukemia,nonlymphocytic,acute%Relapse
目的 研究AML1-ETO9a (AE9a)异构体在伴有t(8；21)的M2型急性髓系白血病( AML-M2)患者中表达比例的变化及其临床意义.方法 应用RT-PCR方法筛选了44例初诊AE9a与AML1-ETO(AE)融合基因共表达的伴有t(8;21)的AML-M2患者.应用实时定量PCR技术监测这44例多次随访标本中AE9a在AE9a与AE两者总和中百分比的变化.结果 伴有t(8;21)的44例初诊AML-M2患者中AE表达量高于AE9a(中位CT值分别为20.48和21.54),两者表达量呈正相关(r =0.900)；44例初诊患者经首次标准方案化疗后AE与AE9a表达量均下降,但初治后AE9a在总体中百分比较初诊时上升(P＜0.05)；患者经1个疗程标准方案化疗后,未达完全缓解(CR)组的AE9a百分比明显高于CR组(中位值分别为36.81％和7.93％,P＜0.05)；复发患者缓解期间AE9a百分比高于未复发患者(中位值分别为22.89％和2.43％,P＜0.05)；缓解期间,17例复发患者中11例AE9a百分比在AE表达低水平时即出现升高甚至异常升高.结论 AE9a与AE共表达于伴有t(8；21)的AML-M2患者中,并且AE表达量高于AE9a,两者呈正相关.AE9a异构体对标准化疗的敏感性较AE差.在缓解期监测AE9a在AE及AE9a两者总体中百分比的变化比单独监测AE融合基因能更早地预示疾病复发趋势,从而可提前进行临床干预,降低患者的复发率,提高患者的长期生存率.
目的 研究AML1-ETO9a (AE9a)異構體在伴有t(8；21)的M2型急性髓繫白血病( AML-M2)患者中錶達比例的變化及其臨床意義.方法 應用RT-PCR方法篩選瞭44例初診AE9a與AML1-ETO(AE)融閤基因共錶達的伴有t(8;21)的AML-M2患者.應用實時定量PCR技術鑑測這44例多次隨訪標本中AE9a在AE9a與AE兩者總和中百分比的變化.結果 伴有t(8;21)的44例初診AML-M2患者中AE錶達量高于AE9a(中位CT值分彆為20.48和21.54),兩者錶達量呈正相關(r =0.900)；44例初診患者經首次標準方案化療後AE與AE9a錶達量均下降,但初治後AE9a在總體中百分比較初診時上升(P＜0.05)；患者經1箇療程標準方案化療後,未達完全緩解(CR)組的AE9a百分比明顯高于CR組(中位值分彆為36.81％和7.93％,P＜0.05)；複髮患者緩解期間AE9a百分比高于未複髮患者(中位值分彆為22.89％和2.43％,P＜0.05)；緩解期間,17例複髮患者中11例AE9a百分比在AE錶達低水平時即齣現升高甚至異常升高.結論 AE9a與AE共錶達于伴有t(8；21)的AML-M2患者中,併且AE錶達量高于AE9a,兩者呈正相關.AE9a異構體對標準化療的敏感性較AE差.在緩解期鑑測AE9a在AE及AE9a兩者總體中百分比的變化比單獨鑑測AE融閤基因能更早地預示疾病複髮趨勢,從而可提前進行臨床榦預,降低患者的複髮率,提高患者的長期生存率.
목적 연구AML1-ETO9a (AE9a)이구체재반유t(8；21)적M2형급성수계백혈병( AML-M2)환자중표체비례적변화급기림상의의.방법 응용RT-PCR방법사선료44례초진AE9a여AML1-ETO(AE)융합기인공표체적반유t(8;21)적AML-M2환자.응용실시정량PCR기술감측저44례다차수방표본중AE9a재AE9a여AE량자총화중백분비적변화.결과 반유t(8;21)적44례초진AML-M2환자중AE표체량고우AE9a(중위CT치분별위20.48화21.54),량자표체량정정상관(r =0.900)；44례초진환자경수차표준방안화료후AE여AE9a표체량균하강,단초치후AE9a재총체중백분비교초진시상승(P＜0.05)；환자경1개료정표준방안화료후,미체완전완해(CR)조적AE9a백분비명현고우CR조(중위치분별위36.81％화7.93％,P＜0.05)；복발환자완해기간AE9a백분비고우미복발환자(중위치분별위22.89％화2.43％,P＜0.05)；완해기간,17례복발환자중11례AE9a백분비재AE표체저수평시즉출현승고심지이상승고.결론 AE9a여AE공표체우반유t(8；21)적AML-M2환자중,병차AE표체량고우AE9a,량자정정상관.AE9a이구체대표준화료적민감성교AE차.재완해기감측AE9a재AE급AE9a량자총체중백분비적변화비단독감측AE융합기인능경조지예시질병복발추세,종이가제전진행림상간예,강저환자적복발솔,제고환자적장기생존솔.
Objective To study the expression ratio of AMLl-ETO9a (AE9a) isoform in t( 8 ;21 )acute myeloid leukemia (AML) and its clinical significance.Methods Bone marrow samples from 44 newly diagnosed t(8 ;21 ) AML patients co-expressed AE9a and AE were screened by RT-PCR.The alteration of the AE9a expression ratio was monitored during follow-up by using quantitative real-time RT-PCR(qPCR).Results The expression level of AE9a was markedly lower than that of AE in these patients.There was a positive correlation between the expression level of AE9a and AE in most of bone marrow samples.The transcript level of both AE9a and AE was decreased in the 44 patients after one course of standard chemotherapy,but the percentage of AE9a expression level was increased in comparison with that before treatment (P ＜0.05 ).After one course of standard chemotherapy treatment,the percentage of AE9a in incomplete remission (ICR)patients was significantly higher than that in CR patients ( P ＜ 0.05 ).Relapsed patients had a higher AE9a ratio than the unrelapsed patients ( P ＜ 0.05 ).During the remission,the percentage of AE9a in 11/17 relapsed patients obviously elevated even while the expression of AE fusion gene at low level.Conclusions AE9a and AE co-expressed in most of AML patients with t(8 ;21 ) translocation.The expression level of AE9a was lower than that of AE,and there is a positive correlation between the expression level of these two isoforms.The sensitivity of AE9a gene to the standard chemotherapy is less than that of the AE fusion gene.Monitoring the AE9a to AE ratio during the CR can predict the early relapse of the disease compared to monitoring the AE alone.
